Shots:
- Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD; n=141) vs bendamustine + rituximab (n=141) in 282 treatment-naïve CLL/SLL pts without 17p deletions
- As of Jul 11, 2025, trial met its 1EP of improved IRC-assessed PFS by 80% with benefits seen across all high-risk subgroups & investigator assessments at an mFU of 28.1mos., while OS data (2EP) showed a favorable trend for Jaypirca despite 52.9% crossover; further OS testing is planned. Data was presented at ASH’25 & published in The JCO
- Additionally, Lilly has started submitting results from the BRUIN CLL-313 & P-III (BRUIN CLL-314) studies to support label expansion of Jaypirca into earlier lines of therapy
Ref: Eli Lilly | Image: Eli Lilly |Press Release
Related News: Eli Lilly’s Omvoh (mirikizumab-mrkz) Receives the US FDA’s Approval for Ulcerative Colitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
